Investment Analysts’ Recent Ratings Updates for Portola Pharmaceuticals (PTLA)

A number of research firms have changed their ratings and price targets for Portola Pharmaceuticals (NASDAQ: PTLA):

  • 2/13/2018 – Portola Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 2/7/2018 – Portola Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/2/2018 – Portola Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/26/2018 – Portola Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/19/2018 – Portola Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/15/2018 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 1/10/2018 – Portola Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 1/4/2018 – Portola Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 1/2/2018 – Portola Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 1/1/2018 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at William Blair.
  • 12/28/2017 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/28/2017 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a $74.00 price target on the stock.
  • 12/21/2017 – Portola Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/19/2017 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Shares of Portola Pharmaceuticals Inc (PTLA) traded up $1.60 during midday trading on Wednesday, hitting $46.70. 360,371 shares of the company’s stock were exchanged, compared to its average volume of 905,786. Portola Pharmaceuticals Inc has a one year low of $29.50 and a one year high of $67.10. The company has a market capitalization of $3,030.00, a P/E ratio of -10.81 and a beta of 1.18. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.

In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.50% of the company’s stock.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply